Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Plasma Type & Surgery The global platelet rich plasma market will witness a robust CAGR of 12.12%, valued at $352.05 million in 2021, expected to appreciate and reach $985.73 million by 2030, confirms Strategic Market Research. Platelets are well-known for their clotting properties, including growth factors that can induce tissue regeneration and repair in the treated region. Platelet-rich plasma blood contains a higher concentration of platelets than normal. It's created by centrifuging human blood and extracting platelet-rich plasma, which has a greater concentration of platelets than normal. Platelets help tendons, muscles, and ligaments recover faster by assisting in blood coagulation. PRP is utilized in various operations, including rotator cuff augmentation and tendon repairing. According to Johns Hopkins University, around 30 million children and adolescents in the United States participate in organized sports. Around 3.5 million injuries occur each year. Key Drivers - Increasing Sports Injuries and Rise in Surgical and Cosmetic Procedures According to data from the US Centers for Disease Control and Prevention (CDC), Individual engagement in sports in the United States is steadily increasing. In the United States, around 30 million children and adolescents participate in sports. Young athletes are more likely to sustain sports injuries due to this. Athletes in high school are responsible for around 2 million injuries, 30,000 hospitalizations, and 500,000 medical visits in the United States. Every year, almost 3.5 million children under the age of 14 need medical care for sports injuries. In 2019, over 18.1 million cosmetic surgeries were performed in the United States, according to the American Society of Plastic Surgeons (ASPS). The number of treatments performed has augmented over the previous five years, and demand for minimally invasive cosmetic surgery has grown across the United States. Liposuction and facelifts are becoming increasingly fashionable. Furthermore, increasing use of platelet-rich plasma in anti-aging, platelet-rich plasma for stretch marks, Eclipse PRP, traumatic injury, Tendon injury, Ligament injury, Muscle injury, Tennis Elbow injury, joint injury, musculoskeletal pain, Osteoarthritis, Hair Loss, Skin Rejuvenation, Fractures are driving the overall market growth significantly. Restraints - Higher Costs of Prosthetic Treatments High prosthetic costs hamper the worldwide orthopedic prosthetics industry. A function below-the-knee prosthesis that lets the user stand and walk on level ground costs between US$ 5,000 and US$ 7,000, while computer-assisted devices cost between US$ 20,000 and US$ 30,000. Industry trends and Opportunities: - (Skin improvement with PRP and increasing cases of inflammatory disorder) In recent times, the ASPS (American Society of Plastic Surgeons) has seen a dramatic surge in the usage of cosmetic PRP. This is clear, as PRP therapies show significant potential in leveraging the body's natural tissue regeneration mechanisms to assist patients in attaining better shape and function, which is likely to provide ample growth opportunities for the PRP Market. During the projected period, the platelet rich plasma market in India is likely to rise rapidly. Because of the high frequency of inflammatory illnesses, the demand is growing. According to Arthritis India, Arthritis affects 15% of the population in India or approximately 210 million individuals. Due to a scarcity of educated rheumatologists in India, untrained physicians, alternative medicine practitioners, and quacks manage these disorders. Arthritis-mission in India is to provide scientific knowledge about arthritis and its related disorders and assist people in overcoming their difficulties. Market Analysis Of Different Segments Covered in the Report Based on Sample type Pure PRP Leukocyte-rich PRP Pure PRF Based on Origin Autologous Allogenic Homologous Based on Application Orthopedic surgery Cosmetic surgery General surgery Neurosurgery Regional Coverage Analysis North America The U.S. Canada Mexico Rest of North America Europe France Germany U.K Spain Italy Rest of Europe Asia Pacific China India Japan Australia Rest of APAC LAMEA Brazil Saudi Arabia South Africa Rest of LAMEA Sample Type Analysis & Insights The Pure PRP segment is projected to grow at the highest rate based on Sample type. The segment's dominance may be attributed to technical improvements in PRP devices, which have led to the usage of pure PRP in various situations, as well as rich platelet content, which are expected to enhance the segment's growth in the coming years. The global platelet rich plasma market has also benefited from technological improvements such as smart home diagnostic kits. Origin Analysis & Insights Based on Origin, Autologous held the largest market share in 2020. Autologous platelet-rich plasma (PRP) is a safe, straightforward, and cost-effective treatment that promotes cell proliferation, migration, and angiogenesis. In the treatment of chronic non-healing ulcers, autologous PRP is quite effective. The need for autologous PRP is likely to rise in developed nations worldwide. According to NCBI, Chronic non-healing ulcers are a serious public health issue that affects an estimated 2–6 million individuals in the United States alone, with global prevalence ranging from 1.9 to 13.1 percent. Application Analysis & Insights Based on the Application, Orthopaedic surgery held the largest market share in 2020. During the projection period, the segment is expected to be driven by an increase in the number of orthopedic procedures. Orthopedists most typically utilize knee and hip prostheses, which allow patients to restore complete range of motion, pain-free, in a very short period. According to the Rehabilitation Research and Training Centre on Disability Statistics and Demographics, In the United States, the percentage of the population with impairments has surged from roughly 11.9 % to 12.9 %. Regional Analysis & Insights Based on Regions, North America is the fastest-growing platelet-rich plasma market. The increased incidence of numerous ailments, such as arthritis, well-established healthcare infrastructure, improved regulatory environment, and government assistance contribute to market expansion in the United States. According to the CDC(Centers for Disease Control and Prevention) report, roughly 54.4 million people (22.7 percent) in the United States have been diagnosed with common arthritis, rheumatoid arthritis, or gout, boosting treatment uptake. Platelet Rich Plasma Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 352.05 Million The revenue forecast in 2030 USD 985.73 Million Growth rate CAGR of approximately 12.12% The base year for estimation 2021 Unit USD Million, CAGR (2021 - 2030) Segmentation By Sample Type, By Origin, By Application, By Region By Sample Type Pure PRP, Leukocyte-rich PRP, Pure PRF By Origin Autologous, Allogenic, Homologous By Application Orthopedic surgery, Cosmetic surgery, General surgery, Neurosurgery By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles SelfDiagnostics, Quidel Corporation, F. Hoffmann-La Roche Ltd., Dickinson and Company, Trinity Biotech plc, Becton, Bionime Corporation, Abbott, ARKRAY, Inc., ACON Laboratories, Inc., and Assure Tech. (Hangzhou) Co., Ltd. Platelet Rich Plasma Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the global environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, industry potential, etc. SelfDiagnostics Quidel Corporation F. Hoffmann-La Roche Ltd. Dickinson and Company Trinity Biotech plc Becton Bionime Corporation Abbott ARKRAY, Inc. ACON Laboratories, Inc. Assure Tech. (Hangzhou) Co., Ltd. Zimmer Biomet Holdings Inc. Royal Biologics Recent Developments In September 2021, The Maxx Concentration system received FDA 510K certification, according to Royal Biologics, an orthobiologics firm specializing in autologous and live cellular treatments. Maxx –PRP is patented next-generation concentration equipment that may be used to concentrate autologous whole blood to manufacture platelet-rich plasma in a safe and efficient manner. In July 2021, Zimmer Biomet Holdings Inc., a global leader in musculoskeletal healthcare, formed a strategic partnership with OSSIS, a hip replacement specialist. In February 2021, Atlas Health Medical Group announced the availability of PRP (Platelet-rich Plasma) Microneedling Facelifts for patients across the globe. Using these PRP Microneedling Facelifts will drive industry growth in the future. In February 2020, EmCyte finalized the acquisition of Cellmedix Holdings LLC, which comprised all of the company's assets, including its patented product system and the Intrepid Platelet Concentrator. List of Products that Market Leaders Develop Name of Product Functions Company Maxx Concentration system It is regarded as patented next-generation concentration equipment that is used to concentrate autologous whole blood for the manufacture of platelet-rich plasma in a safe and efficient manner. Royal Biologics PRP (Platelet-rich Plasma) Microneedling Facelifts Stimulates collagen production & cell migration, thus eliminating lines, folds, & wrinkles of the skin. Atlas Health Medical Group Intrepid Platelet Concentrator Used for preventing or treating bleeding in people with either poor platelet function or a low platelet count. EmCyte Frequently Asked Question About This Report How big is the platelet rich plasma market? The global platelet rich plasma market size was around $352.05 million in 2021 and is predicted to reach $394.72 million in 2022. What is the current value of the market? The global market size was around USD 352.05 million in 2021, and it is forecasted to grow at a CAGR of 12.12% from 2020 to 2030. Thus, the industry forecast suggests that it will reach a landmark of around USD 985.73 million by 2030. At what rate did the industry grow between 2016 and 2020? The growth rate was around 12% between 2016 and 2020. What was the last five years CAGR for platelet-rich plasma therapy? The CAGR for platelet-rich plasma therapy was around 12% in the last five years. How successful is platelet-rich plasma? Nearly 84% of the patients who got PRP injections reported a 25% or higher improvement in pain after 24 weeks, compared to 68.3% of the control group. The Eclipse PRP system is a highly safe injection method that can give a natural and effective alternative to many of todays manufactured or surgical therapy alternatives for everything from facial rejuvenation to hair loss and beyond. How much does platelet-rich plasma Cost in the U.K.? The average cost of PRP injection sessions in the United Kingdom is roughly £350. PRP treatments at Dynamic Regenerative Medicine cost between £150 and £250. What is the platelet rich plasma market growth? The global platelet rich plasma market is expected to grow at a compound annual growth rate (CAGR) of 12.12% from 2021 to 2030 to reach USD 985.73 million by 2030. Source:- https://www.jhu.edu/ http://www.cdc.gov/ https://plasticsurgery.org/ http://nhp.gov.in/disease/musculo-skeletal-bone-joints-/arthritis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327512/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Platelet Rich Plasma Industry 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global Market, by Region, 2021 - 2030 (USD Million) 4.4 By Sample Type Business Analysis 4.4.1 Global Market, By Sample Type, 2021 - 2030 (USD Million) 4.5 By Origin Business Analysis 4.5.1 Global Market, By Origin, 2021 - 2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Global Market, By Application, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Platelet Rich Plasma Manufacturing Sites, Area Served, Product Sample Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Sample Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Pure PRP 7.3.1. Pure PRP market, 2021 - 2030 (USD Million) 7.4. Leukocyte-rich PRP 7.4.1. Leukocyte-rich PRP market, 2021 - 2030 (USD Million) 7.5. Pure PRF 7.5.1. Pure PRF market, 2021 - 2030 (USD Million) 8. Global Market: By Origin Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Autologous 8.3.1. Autologous market, 2021 - 2030 (USD Million) 8.4. Allogenic 8.4.1. Allogenic market, 2021 - 2030 (USD Million) 8.5. Homologous 8.5.1. Homologous market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Orthopedic surgery 9.3.1. Orthopedic surgery market, 2021 - 2030 (USD Million) 9.4. Cosmetic surgery 9.4.1. Cosmetic surgery market, 2021 - 2030 (USD Million) 9.5. General surgery 9.5.1. General surgery market, 2021 - 2030 (USD Million) 9.6. Neurosurgery 9.6.1. Neurosurgery market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America Market, By Sample Type, 2021 - 2030 (USD Million) 10.1.2. North America Market, By Origin, 2021 - 2030 (USD Million) 10.1.3. North America Market, by Application, 2021 - 2030 (USD Million) 10.1.4. North America Market, by Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, By Sample Type, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S. Market, By Origin, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S. Market, by Application, 2021 - 2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada Market, By Sample Type, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada Market, By Origin, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada Market, by Application, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, By Sample Type, 2021 - 2030 (USD Million) 10.2.2. Europe Market, By Origin, 2021 - 2030 (USD Million) 10.2.3. Europe Market, by Application, 2021 - 2030 (USD Million) 10.2.4. Europe Market, by country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, By Sample Type, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. Market, By Origin, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. Market, by Application, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, By Sample Type, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany Market, By Origin, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany Market, by Application, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, By Sample Type, 2021 - 2030 (USD Million) 10.2.4.3.2. France Market, By Origin, 2021 - 2030 (USD Million) 10.2.4.3.3. France Market, by Application, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, By Sample Type, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, By Origin, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, by Application, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific Market, By Origin, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific Market, by Application, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.4.1.2. China Market, By Origin, 2021 - 2030 (USD Million) 10.3.4.1.3. China Market, by Application, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.4.2.2. India Market, By Origin, 2021 - 2030 (USD Million) 10.3.4.2.3. India Market, by Application, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan Market, By Origin, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan Market, by Application, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea Market, By Origin, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea Market, by Application, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, By Sample Type, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, By Origin, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, by Application, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, By Sample Type, 2021 - 2030 (USD Million) 10.4.2. Latin America Market, By Origin, 2021 - 2030 (USD Million) 10.4.3. Latin America Market, by Application, 2021 - 2030 (USD Million) 10.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, By Sample Type, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil Market, By Origin, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil Market, by Application, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, By Sample Type, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico Market, By Origin, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico Market, by Application, 2021 - 2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America Market, By Sample Type, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, By Origin, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, by Application, 2021 - 2030 (USD Million) 10.5. LAMEA 10.5.1. LAMEA Market, By Sample Type, 2021 - 2030 (USD Million) 10.5.2. LAMEA Market, By Origin, 2021 - 2030 (USD Million) 10.5.3. LAMEA Market, by Application, 2021 - 2030 (USD Million) 10.5.4. LAMEA Market, by Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 Self-Diagnostics 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. QUIDEL CORPORATION 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. F. HOFFMANN-LA ROCHE LTD. 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. DICKINSON AND COMPANY 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. TRINITY BIOTECH PLC 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Becton 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Bionime Corporation 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Abbott 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. ARKRAY, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. ACON Laboratories, Inc. 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Assure Tech. (Hangzhou) Co., Ltd. 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development List of Tables (56 Tables) TABLE 1. Market, By Sample Type, 2021-2030 (USD Million) TABLE 2. Market FOR Pure PRP, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Leukocyte-rich PRP, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Pure PRF, BY REGION, 2021-2030 (USD Million) TABLE 5. Market, By Origin, 2021-2030 (USD Million) TABLE 6. Market FOR Autologous, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Allogenic, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Homologous, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Food & Beverages, BY REGION, 2021-2030 (USD Million) TABLE 10.Market FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 11.Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 12.Market FOR Orthopaedic surgery, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Cosmetic surgery, BY REGION, 2021-2030 (USD Million) TABLE 14. Market FOR General surgery, BY REGION, 2021-2030 (USD Million) TABLE 15. Market FOR Neurosurgery, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 17. Market FOR Battery Powered Platelet Rich Plasma, BY REGION, 2021-2030 (USD Million) TABLE 18. Market, BY REGION, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, By Sample Type, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, By Origin, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 23. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. EUROPE Market, By Sample Type, 2021-2030 (USD Million) TABLE 25. EUROPE Market, By Origin, 2021-2030 (USD Million) TABLE 26. EUROPE Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC Market, By Sample Type, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC Market, By Origin, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. LAMEA Market, By Sample Type, 2021-2030 (USD Million) TABLE 33. LAMEA Market, By Origin, 2021-2030 (USD Million) TABLE 34. LAMEA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 35. Self-Diagnostics: COMPANY SNAPSHOT TABLE 36. Self-Diagnostics: OPERATING SEGMENTS TABLE 37. QUIDEL CORPORATION: COMPANY SNAPSHOT TABLE 38. QUIDEL CORPORATION: OPERATING SEGMENTS TABLE 39. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT TABLE 40. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS TABLE 41. DICKINSON AND COMPANY: COMPANY SNAPSHOT TABLE 42. DICKINSON AND COMPANY: OPERATING SEGMENTS TABLE 43. TRINITY BIOTECH PLC: COMPANY SNAPSHOT TABLE 44. TRINITY BIOTECH PLC: OPERATING SEGMENTS TABLE 45. Becton: COMPANY SNAPSHOT TABLE 46. Becton: OPERATING SEGMENTS TABLE 47. Bionime Corporation: COMPANY SNAPSHOT TABLE 48. Bionime Corporation: OPERATING SEGMENTS TABLE 49. Doosan Robotics: COMPANY SNAPSHOT TABLE 50. Doosan Robotics: OPERATING SEGMENTS TABLE 51. ARKRAY, Inc.: COMPANY SNAPSHOT TABLE 52. ARKRAY, Inc.: OPERATING SEGMENTS TABLE 53. ACON Laboratories, Inc.: COMPANY SNAPSHOT TABLE 54. ACON Laboratories, Inc.: OPERATING SEGMENTS TABLE 55. Assure Tech. (Hangzhou) Co., Ltd.: COMPANY SNAPSHOT TABLE 56. Assure Tech. (Hangzhou) Co., Ltd.: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 11 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Platelet Rich Plasma, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Platelet Rich Plasma, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Origin, 2019 vs 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs 2025 (USD Million) Figure 13 Market Share, By Sample Type, 2019 vs 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Pure PRP Market to Witness Higher CAGR in Market for Sample Type Segment during Forecast Period. Figure 16 Orthopedic surgery to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 17Autologous to Witness Higher CAGR in Market for Origin Segment during Forecast Period. Figure 18 North America Region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview